The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis

International Journal of General Medicine

Volumn 3, Issue , 2010, Pages 31-36

  Stephens, Jennifer ^a   Carpiuc, Kimbach Tran ^a   Botteman, Marc ^a  

^a PHARMERIT INTERNATIONAL   (United States)

Author keywords

Adverse events; And cost analysis; Cost; Dasatinib; Imatinib; Nilotinib; Safety

Indexed keywords

DASATINIB; DIURETIC AGENT; FUROSEMIDE; IMATINIB; PREDNISONE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; INVASIVE PROCEDURE; LUNG ARTERY CATHETER; LUNG VOLUME; PLEURA EFFUSION; PROBABILITY; RECURRENT DISEASE; SENSITIVITY ANALYSIS; TUBE;

EID: 77953373231     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
2. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib- resistant CML. Nature Rev Cancer. 2007;7(5):345-356.
3. Bristol-Myers Squibb Company. Sprycel (dasatinib) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2008.
4. Novartis Pharmaceuticals. Tasigna (nilotinib) prescribing information. Florham Park, NJ: Novartis Pharmaceuticals; 2007.
5. Koledin M, Duric D, Milovancev A, Bijelovic M, Baros B. Pleural effusions of malignant etiology: diagnostics, treatment and quality of life. Arch Oncol. 2001;9(1):3-7.
6. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908-3914.
7. Quintas-Cardama A, Kantarjian HM, Munden R, et al. Pleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure (abstract). ASH Annual Meeting. Blood. 2006;1:108(11):2164.
8. Ingenix. National Fee Analyzer: Charge data for evaluating fees nationally. Eden Prairie, MN: Ingenix; 2006.
9. Ingenix. Outpatient billing expert. Eden Prairie, MN: Ingenix; 2006.
10. Putnam JB Jr, Walsh GL, Swisher SG, et al. Outpatient manage ment of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg. 2000;69(2):369-375.
11. Girardi LN, Ginsberg RJ, Burt ME. Pericardiocentesis and intrapericardial sclerosis: effective therapy for malignant pericardial effusions. Ann Thorac Surg. 1997;64(5):1422-1427.
12. Thomson Healthcare. Red Book. Montvale, NJ: Thomson Health care; 2008.
13. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204-3212.